Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 4 | 7 |
| List of Tables | 7 | 2 |
| List of Figures | 9 | 2 |
| Orphan Diseases Therapeutics in Oncology - Introduction | 11 | 4 |
| Introduction | 11 | 1 |
| Introduction to Cancer Etiology | 11 | 1 |
| Drug Classes and their Mechanisms of Action in the Treatment of Cancer | 12 | 2 |
| GBI Research Report Guidance | 14 | 1 |
| Orphan Diseases Therapeutics in Oncology - Market Overview | 15 | 4 |
| Revenues | 15 | 1 |
| Annual Cost of Therapy | 16 | 1 |
| Treatment Usage Pattern | 17 | 1 |
| Diseased Population | 18 | 1 |
| Diagnosed Population | 18 | 1 |
| Prescription Population | 18 | 1 |
| Orphan Diseases Therapeutics in Oncology - Geographical Landscape | 19 | 14 |
| Introduction | 19 | 1 |
| The US | 19 | 1 |
| Sales Revenues | 19 | 2 |
| ACT | 21 | 1 |
| Treatment Usage Patterns | 22 | 1 |
| Diseased Population | 23 | 1 |
| Diagnosed Population | 23 | 1 |
| Prescription Population | 23 | 1 |
| Top Five Countries of Europe | 24 | 1 |
| Sales Revenues | 24 | 2 |
| ACT | 26 | 1 |
| Treatment Usage Patterns | 27 | 1 |
| Diseased Population | 28 | 1 |
| Diagnosed Population | 28 | 1 |
| Prescription Population | 28 | 1 |
| Japan | 29 | 1 |
| Sales Revenues | 29 | 1 |
| ACT | 30 | 1 |
| Treatment Usage Patterns | 31 | 1 |
| Diseased Population | 32 | 1 |
| Diagnosed Population | 32 | 1 |
| Prescription Population | 32 | 1 |
| Orphan Diseases Therapeutics in Oncology - Therapeutic Landscape | 33 | 37 |
| Pancreatic Cancer Therapeutics Market | 33 | 1 |
| Introduction | 33 | 1 |
| Epidemiology | 33 | 1 |
| Symptoms | 33 | 1 |
| Treatment | 34 | 1 |
| Sales Revenues | 34 | 2 |
| ACT | 36 | 1 |
| Treatment Usage Patterns | 37 | 1 |
| Diseased Population | 38 | 1 |
| Diagnosed Population | 38 | 1 |
| Prescription Population | 38 | 1 |
| Marketed Products | 38 | 1 |
| Gemzar (gemcitabine) | 38 | 1 |
| Tarceva (erlotinib) | 38 | 1 |
| Drivers and Barriers in the Pancreatic Cancer Therapeutics Market | 39 | 1 |
| Drivers | 39 | 1 |
| Barriers | 40 | 1 |
| Ovarian Cancer Therapeutics Market | 41 | 1 |
| Introduction | 41 | 1 |
| Epidemiology | 41 | 1 |
| Symptoms | 41 | 1 |
| Treatment | 41 | 1 |
| Sales Revenues | 42 | 1 |
| ACT | 43 | 1 |
| Treatment Usage Patterns | 44 | 1 |
| Diseased Population | 45 | 1 |
| Diagnosed Population | 45 | 1 |
| Prescription Population | 45 | 1 |
| Marketed Products | 45 | 1 |
| Topotecan | 45 | 1 |
| Doxil (pegylated liposomal doxorubicin) | 45 | 1 |
| Avastin (bevacizumab) | 45 | 1 |
| Paclitaxel | 46 | 1 |
| Carboplatin | 46 | 1 |
| Drivers and Barriers in the Ovarian Cancer Therapeutics Market | 46 | 1 |
| Drivers | 46 | 1 |
| Barriers | 47 | 1 |
| Multiple Myeloma Therapeutics Market | 47 | 1 |
| Introduction | 47 | 1 |
| Epidemiology | 47 | 1 |
| Symptoms | 47 | 1 |
| Treatment | 48 | 1 |
| Sales Revenues | 49 | 1 |
| ACT | 50 | 1 |
| Treatment Usage Patterns | 51 | 1 |
| Diseased Population | 52 | 1 |
| Diagnosed Population | 52 | 1 |
| Prescription Population | 52 | 1 |
| Marketed Products | 52 | 1 |
| Velcade (bortezomib) | 52 | 1 |
| Revlimid (lenalidomide) | 53 | 1 |
| Thalomid (thalidomide) | 53 | 1 |
| Dexamethasone | 53 | 1 |
| Prednisone | 53 | 1 |
| Melphalan | 53 | 1 |
| Cyclophosphamide | 53 | 1 |
| Drivers and Barriers in the Multiple Myeloma Therapeutics Market | 54 | 1 |
| Drivers | 54 | 1 |
| Barriers | 54 | 1 |
| Acute Myeloid Leukemia Therapeutics Market | 55 | 1 |
| Introduction | 55 | 1 |
| Epidemiology | 55 | 1 |
| Symptoms | 55 | 1 |
| Treatment | 56 | 1 |
| Sales Revenues | 57 | 1 |
| ACT | 58 | 1 |
| Treatment Usage Patterns | 59 | 1 |
| Diseased Population | 60 | 1 |
| Diagnosed Population | 60 | 1 |
| Prescription Population | 60 | 1 |
| Marketed Products | 60 | 1 |
| Vidaza (azacytidine) | 60 | 1 |
| Cytarabine | 60 | 1 |
| Daunorubicin | 60 | 1 |
| Idarubicin | 61 | 1 |
| Drivers and Barriers in the Acute Myeloid Leukemia Therapeutics Market | 61 | 1 |
| Drivers | 61 | 1 |
| Barriers | 62 | 1 |
| Hodgkin Lymphoma Therapeutics Market | 62 | 1 |
| Introduction | 62 | 1 |
| Epidemiology | 62 | 1 |
| Symptoms | 62 | 1 |
| Treatment | 63 | 1 |
| Sales Revenues | 64 | 1 |
| ACT | 65 | 1 |
| Treatment Usage Pattern | 66 | 1 |
| Diseased Population | 67 | 1 |
| Diagnosed Population | 67 | 1 |
| Prescription Population | 67 | 1 |
| Marketed Products | 67 | 1 |
| Adcetris (Brentuximab vedotin) | 67 | 1 |
| Doxorubicin | 67 | 1 |
| Bleomycin | 67 | 1 |
| Dacarbazine | 67 | 1 |
| Procarbazine | 67 | 1 |
| Vinblastine | 68 | 1 |
| Vincristine | 68 | 1 |
| 7Etoposide | 68 | 1 |
| Cyclophosphamide | 68 | 1 |
| Drivers and Barriers in the Hodgkin Lymphoma Therapeutic Market | 68 | 1 |
| Drivers | 69 | 1 |
| Barriers | 69 | 1 |
| Orphan Diseases Therapeutics in Oncology - Pipeline Analysis | 70 | 34 |
| Introduction | 70 | 1 |
| R&D Pipeline for Pancreatic Cancer | 71 | 1 |
| Phase III | 72 | 1 |
| Phase II | 72 | 1 |
| Phase I | 73 | 1 |
| IND Filed | 74 | 1 |
| Preclinical | 75 | 2 |
| Discovery | 77 | 1 |
| Trends in the Pancreatic Cancer Developmental Pipeline | 77 | 1 |
| Promising Pipeline Molecules | 78 | 1 |
| FOLFIRINOX | 78 | 1 |
| AMG-479 | 78 | 1 |
| Masitinib | 78 | 1 |
| R&D Pipeline for Ovarian Cancer | 79 | 1 |
| Phase III | 80 | 1 |
| Phase II | 81 | 2 |
| Phase I | 83 | 1 |
| Preclinical | 84 | 1 |
| Discovery | 85 | 1 |
| Trends in the Ovarian Cancer Developmental Pipeline | 85 | 1 |
| Promising Pipeline Molecules | 86 | 1 |
| EC145 | 86 | 1 |
| Vargatef | 86 | 1 |
| R&D Pipeline for Multiple Myeloma | 87 | 1 |
| Phase III | 88 | 1 |
| Phase II | 88 | 2 |
| Phase I | 90 | 1 |
| Preclinical | 91 | 1 |
| Trends in the Multiple Myeloma Developmental Pipeline | 92 | 1 |
| Promising Pipeline Molecules | 93 | 1 |
| Pomalidomide | 93 | 1 |
| Panobinostat | 93 | 1 |
| Perifosine | 93 | 1 |
| Carfilzomib | 93 | 1 |
| R&D Pipeline for Acute Myeloid Leukemia | 94 | 1 |
| Phase III | 95 | 1 |
| Phase II | 95 | 2 |
| Phase I | 97 | 1 |
| Preclinical | 98 | 1 |
| Discovery | 98 | 1 |
| Trends in the Acute Myeloid Leukemia Developmental Pipeline | 99 | 1 |
| Promising Pipeline Molecules | 100 | 1 |
| Clolar (clofarabine) | 100 | 1 |
| R&D Pipeline for Hodgkin Lymphoma | 100 | 1 |
| NDA Filed | 101 | 1 |
| Phase III | 101 | 1 |
| Phase II | 101 | 1 |
| Phase I | 102 | 1 |
| Trends in the Hodgkin Lymphoma Developmental Pipeline | 102 | 1 |
| Promising Pipeline Molecules | 103 | 1 |
| Panobinostat | 103 | 1 |
| Orphan Diseases Therapeutics in Oncology Therapeutics Market - Competitive Landscape | 104 | 5 |
| Celgene Corporation | 104 | 1 |
| SWOT Analysis | 104 | 1 |
| Genentech, Inc. | 105 | 1 |
| SWOT Analysis | 105 | 1 |
| Amgen, Inc. | 106 | 1 |
| SWOT Analysis | 106 | 1 |
| Eli Lilly and Company | 107 | 1 |
| SWOT Analysis | 107 | 1 |
| Takeda Pharmaceutical Company Ltd. | 108 | 1 |
| SWOT Analysis | 108 | 1 |
| Orphan Diseases Therapeutics in Oncology - M&A, Licensing and Co-Development Landscape | 109 | 14 |
| Overview | 109 | 1 |
| M&A Landscape | 109 | 1 |
| M&A Deals by Year | 109 | 1 |
| M&A Deals by Geography | 110 | 1 |
| M&A Deals by Value | 111 | 1 |
| M&A Deals by Deal Type | 112 | 1 |
| Major M&A Deals | 112 | 1 |
| Sanofi Acquired Genzyme Corporation | 112 | 1 |
| Takeda Pharmaceutical Company Acquires Millennium Pharmaceuticals | 112 | 1 |
| Teva Pharmaceutical Industries Acquires Cephalon Inc. | 112 | 1 |
| Fresenius Kabi AG Acquires APP Pharmaceuticals | 113 | 1 |
| Astellas Pharma Acquires OSI Pharmaceuticals | 113 | 1 |
| Celgene Corporation Acquires Abraxis Bioscience | 113 | 1 |
| Celgene Corporation Acquires Pharmion Corporation | 113 | 1 |
| Bristol-Myers Squibb Acquires Medarex, Inc. | 113 | 1 |
| Amgen Inc. Acquires BioVex Group | 113 | 1 |
| R&D Licensing Agreements | 114 | 1 |
| Deals by Year | 114 | 1 |
| Deals by Geography | 115 | 1 |
| Deals by Value | 116 | 1 |
| Major Licensing Agreements | 117 | 1 |
| Genentech (Roche) Enters into Licensing Agreement with Seattle Genetics | 117 | 1 |
| Bristol-Myers Squibb Enters into Licensing Agreement with Innate Pharma for IPH2102 | 117 | 1 |
| Clavis Pharma Enters into Licensing Agreement with Clovis Oncology | 117 | 1 |
| Onyx Pharmaceuticals Enters into Licensing Agreement with Ono Pharmaceutical for Carfilzomib and ONX 0912 | 117 | 1 |
| Clinical Data Enters into Licensing Agreement with CombinatoRx | 118 | 1 |
| Clovis Oncology Enters into Licensing Agreement with Pfizer for PF-01367338 | 118 | 1 |
| 4SC Enters into Licensing Agreement with Yakult Honsha for Resminostat | 118 | 1 |
| Co-Development Agreements | 119 | 1 |
| Deals by Year | 119 | 1 |
| Deals by Geography | 120 | 1 |
| Deals by Value | 121 | 1 |
| Major Co-Development Agreements | 122 | 1 |
| Bristol-Myers Squibb Enters into an Agreement with PDL BioPharma | 122 | 1 |
| Ambit Biosciences Enters into Co-Development Agreement with Astellas Pharma | 122 | 1 |
| Orphan Diseases Therapeutics in Oncology - Appendix | 123 | 6 |
| Market Definitions | 123 | 1 |
| Abbreviations | 123 | 1 |
| Sources | 124 | 1 |
| Research Methodology | 124 | 5 |
| Coverage | 124 | 1 |
| Secondary Research | 124 | 1 |
| Primary Research | 125 | 1 |
| Therapeutic Landscape | 125 | 1 |
| Epidemiology-based Forecasting | 125 | 2 |